vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and ONESPAWORLD HOLDINGS Ltd (OSW). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $242.1M, roughly 1.0× ONESPAWORLD HOLDINGS Ltd). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 5.0%, a 6.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 11.5%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $14.9M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 7.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ANIP vs OSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $242.1M |
| Net Profit | $27.5M | $12.1M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 6.8% |
| Net Margin | 11.1% | 5.0% |
| Revenue YoY | 29.6% | 11.5% |
| Net Profit YoY | 367.5% | -16.2% |
| EPS (diluted) | $1.14 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $242.1M | ||
| Q3 25 | $227.8M | $258.5M | ||
| Q2 25 | $211.4M | $240.7M | ||
| Q1 25 | $197.1M | $219.6M | ||
| Q4 24 | $190.6M | $217.2M | ||
| Q3 24 | $148.3M | $241.7M | ||
| Q2 24 | $138.0M | $224.9M | ||
| Q1 24 | $137.4M | $211.2M |
| Q4 25 | $27.5M | $12.1M | ||
| Q3 25 | $26.6M | $24.3M | ||
| Q2 25 | $8.5M | $19.9M | ||
| Q1 25 | $15.7M | $15.3M | ||
| Q4 24 | $-10.3M | $14.4M | ||
| Q3 24 | $-24.2M | $21.6M | ||
| Q2 24 | $-2.3M | $15.8M | ||
| Q1 24 | $18.2M | $21.2M |
| Q4 25 | 14.1% | 6.8% | ||
| Q3 25 | 15.9% | 10.2% | ||
| Q2 25 | 6.6% | 9.2% | ||
| Q1 25 | 13.3% | 7.7% | ||
| Q4 24 | -2.3% | 7.9% | ||
| Q3 24 | -13.8% | 10.3% | ||
| Q2 24 | 3.7% | 8.4% | ||
| Q1 24 | 14.8% | 8.0% |
| Q4 25 | 11.1% | 5.0% | ||
| Q3 25 | 11.7% | 9.4% | ||
| Q2 25 | 4.0% | 8.3% | ||
| Q1 25 | 8.0% | 7.0% | ||
| Q4 24 | -5.4% | 6.6% | ||
| Q3 24 | -16.3% | 8.9% | ||
| Q2 24 | -1.7% | 7.0% | ||
| Q1 24 | 13.2% | 10.0% |
| Q4 25 | $1.14 | $0.12 | ||
| Q3 25 | $1.13 | $0.23 | ||
| Q2 25 | $0.36 | $0.19 | ||
| Q1 25 | $0.69 | $0.15 | ||
| Q4 24 | $-0.45 | $0.13 | ||
| Q3 24 | $-1.27 | $0.20 | ||
| Q2 24 | $-0.14 | $0.15 | ||
| Q1 24 | $0.82 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $16.3M |
| Total DebtLower is stronger | — | $84.0M |
| Stockholders' EquityBook value | $540.7M | $542.6M |
| Total Assets | $1.4B | $707.1M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $16.3M | ||
| Q3 25 | $262.6M | $29.6M | ||
| Q2 25 | $217.8M | $35.0M | ||
| Q1 25 | $149.8M | $22.6M | ||
| Q4 24 | $144.9M | $57.4M | ||
| Q3 24 | $145.0M | $48.8M | ||
| Q2 24 | $240.1M | $62.5M | ||
| Q1 24 | $228.6M | $65.4M |
| Q4 25 | — | $84.0M | ||
| Q3 25 | — | $85.2M | ||
| Q2 25 | — | $96.2M | ||
| Q1 25 | — | $97.4M | ||
| Q4 24 | — | $98.6M | ||
| Q3 24 | — | $98.7M | ||
| Q2 24 | — | $123.8M | ||
| Q1 24 | — | $138.6M |
| Q4 25 | $540.7M | $542.6M | ||
| Q3 25 | $505.8M | $552.8M | ||
| Q2 25 | $436.8M | $548.3M | ||
| Q1 25 | $418.6M | $530.6M | ||
| Q4 24 | $403.7M | $554.5M | ||
| Q3 24 | $405.9M | $540.1M | ||
| Q2 24 | $455.8M | $532.7M | ||
| Q1 24 | $452.0M | $515.5M |
| Q4 25 | $1.4B | $707.1M | ||
| Q3 25 | $1.4B | $732.6M | ||
| Q2 25 | $1.3B | $731.8M | ||
| Q1 25 | $1.3B | $708.7M | ||
| Q4 24 | $1.3B | $746.4M | ||
| Q3 24 | $1.3B | $734.0M | ||
| Q2 24 | $920.8M | $756.8M | ||
| Q1 24 | $914.5M | $763.6M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $20.0M |
| Free Cash FlowOCF − Capex | $29.1M | $14.9M |
| FCF MarginFCF / Revenue | 11.8% | 6.2% |
| Capex IntensityCapex / Revenue | 0.5% | 2.1% |
| Cash ConversionOCF / Net Profit | 1.10× | 1.65× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $68.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $20.0M | ||
| Q3 25 | $44.1M | $33.2M | ||
| Q2 25 | $75.8M | $20.3M | ||
| Q1 25 | $35.0M | $10.1M | ||
| Q4 24 | $15.9M | $16.6M | ||
| Q3 24 | $12.5M | $28.6M | ||
| Q2 24 | $17.4M | $18.7M | ||
| Q1 24 | $18.3M | $15.0M |
| Q4 25 | $29.1M | $14.9M | ||
| Q3 25 | $38.0M | $27.6M | ||
| Q2 25 | $71.8M | $17.6M | ||
| Q1 25 | $32.5M | $8.4M | ||
| Q4 24 | $13.5M | $13.2M | ||
| Q3 24 | $7.7M | $27.5M | ||
| Q2 24 | $13.0M | $17.6M | ||
| Q1 24 | $13.7M | $13.7M |
| Q4 25 | 11.8% | 6.2% | ||
| Q3 25 | 16.7% | 10.7% | ||
| Q2 25 | 34.0% | 7.3% | ||
| Q1 25 | 16.5% | 3.8% | ||
| Q4 24 | 7.1% | 6.1% | ||
| Q3 24 | 5.2% | 11.4% | ||
| Q2 24 | 9.4% | 7.8% | ||
| Q1 24 | 10.0% | 6.5% |
| Q4 25 | 0.5% | 2.1% | ||
| Q3 25 | 2.7% | 2.2% | ||
| Q2 25 | 1.9% | 1.1% | ||
| Q1 25 | 1.3% | 0.8% | ||
| Q4 24 | 1.3% | 1.5% | ||
| Q3 24 | 3.2% | 0.5% | ||
| Q2 24 | 3.2% | 0.5% | ||
| Q1 24 | 3.3% | 0.6% |
| Q4 25 | 1.10× | 1.65× | ||
| Q3 25 | 1.66× | 1.36× | ||
| Q2 25 | 8.87× | 1.02× | ||
| Q1 25 | 2.23× | 0.66× | ||
| Q4 24 | — | 1.15× | ||
| Q3 24 | — | 1.33× | ||
| Q2 24 | — | 1.19× | ||
| Q1 24 | 1.00× | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
